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Background: Dioscorea villosa (DV) has been used in Brazil as an alternative medicine to attenuate menopause
symptoms, as well as for the treatment of joint pain and rheumatoid arthritis. In spite of the popular use of DV for
the treatment of various disorders, there are limited scientific data regarding safety aspects of this herb. In this
regard, we carried out to evaluated both antinociceptive and anti-inflammatory activities in experimental models
and assess the toxic effects of the acute (single dose) and subchronic (30 days) oral administration of dry extract of
Dioscorea villosa in rodents.
Methods: The LC analyses were performed to assess the presence of the diosgenin in samples of DV. The
antinociceptive study of DV was performed using models of acetic acid-induced writhing and formalin-induced
pain in mice. The anti-inflammatory study was accomplished by leukocyte migration to the peritoneal cavity. A dry
extract of DV was tested at doses of 100, 200 and 400 mg/kg (per os or p.o.). The toxicological properties of the dry
extract were evaluated by toxicity assays of acute (5 g/kg, single dose) and subchronic (1 g/kg/day, 30 days)
treatment. Haematological, biochemical, and histopathological parameters were studied. The results are expressed
as mean ± S.D., and statistical analysis of the data were performed with the Student’s t-test or one-way analysis of
variance (ANOVA) followed by Tukey’s test. In all cases differences were considered significant if p < 0.05.
Results: HPLC-DAD analysis of the extract from DV revealed the presence of diosgenin as the major compound.
Doses of 200 and 400 mg⁄kg significantly reduced the amount of acetic acid-induced writhing in relation to the
vehicle (p < 0.0001). In the first phase, using the formalin-induced neurogenic pain test, only the 400 mg/kg dose of
DV showed significant inhibition of neurogenic pain (p < 0.001). In the second phase, 200 and 400 mg/kg of DV
showed significant inhibition of inflammatory pain (p < 0.0001). Significant inhibition of leukocyte migration was
observed with doses of 100 (p < 0.001), 200 (p < 0.01) and 400 mg/kg (p < 0.01). Haematological, biochemical and
histopathological data obtained in both acute and subchronic toxicological assays revealed only unremarkable
changes, which are unlikely to indicate DV toxicity with oral administration.
Conclusion: We found that DV possesses antinociceptive and anti-inflammatory properties in rodent models. In
addition, no acute or subchronic toxicity was evident when the herbal extract was administered orally. These results
supporting the folkloric usage of the plant to treat various inflammatory diseases.
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Ethnopharmacology is the cross-cultural scientific study
of ethnic groups and their common knowledge about
the use of plants in health care. Such ethnic knowledge
of the herbal has been largely used to provide support
for the production of medicines in order to improve the
life quality of the populations [1,2]. In Brazil, the use of
products derived from medicinal plants is regulated by
the National Agency of Sanitary Surveillance through
the law of herbal medicines (RDC n° 14 of 31/03/2010),
which aims to ensure the quality of herbal products [3].
Several factors have encouraged the increasing use of
herbal medicine in Brazil, such as biodiversity, variety of
pharmacological activities, low cost to patients, reduced
side effects and toxicity as well as a large acceptance of
products based on medicinal plants. However, despite
the advantages associated with natural products, it has
been reported that their inadvertent overuse can damage
health [1,4-6].
There is a strong trend in the use of natural sub-
stances with therapeutic activity, particularly in diseases
in which clinically used synthetic drugs, such as anal-
gesic, anti-inflammatory and hormonal drugs have sev-
eral complications and side effects. These adverse
reactions have propelled the search for safer alternative
therapies in the last decades, such as the use of herbal
products [1,2,7].
Dioscorea villosa (DV), commonly known as “yam”, is a
medicinal woodland herb native from the temperate forests
of eastern North America. The chemical composition of
DV includes protodioscin, methylprotodioscin, dioscine,
prosapogenin, epiafzelechin glucopyranoside, saponin gly-
cosides, steroidal saponin, diosgenin, alkaloids, tannins and
phytoestrogen [8-12]. In addition, the rhizomes and roots
of DV have been popularly used as a non-conventional
treatment of the symptoms of menopause [13,14], rheuma-
toid arthritis and hypoprogesteronaemia [8,11].
The safety, relatively low cost and easy availability of
natural active products make them relevant models for
the synthesis of more selective and powerful drugs. Al-
though a considerable number of analgesic and anti-
inflammatory drugs are currently available for clinical
usage, the wide range of side-effects has led to the
search for new compounds based on safer herbal medi-
cine [6,15-17].
Despite the popular use of DV for the treatment of
various disorders, there is limited scientific data available
regarding the safety aspects of this herb, and there are
no documented toxicological and pharmacologic studies
asserting the safety index of herbal preparations. There-
fore, the current study aimed to assess the toxicological
(acute and subchronic) and pharmacological (anti-inflam-
matory and antinociceptive) properties of the dry extract
of Dioscorea villosa in a rodent model.Methods
Plant material
The dry extract of the Dioscorea villosa (DV) root was
obtained from Shaanxi Meih Biochemics Co., Ltd. (Lot
number MH-06DI-090609), China (imported by Galena
Química e Farmacêutica Ltda company, São Paulo, SP,
Brazil).
Reagents
Diosgenin (≥93%) was purchased from Sigma-Aldrich (St.
Louis, MO, USA), LC-grade acetonitrile (JT Baker,
Philipsburg, PA, USA) was used for LC analysis and
methanol (Tedia, Fairfield, OH, USA) was used for sample
preparation. Deionized water was purified by a Milli-Q
system (Millipore, São Paulo, SP, Brazil). All the solvents
were filtered through nylon 0.45 μm membranes (MFS)
and degassed by ultrasonic bath before use.
Phytochemical studies
The LC analyses were performed on a Shimadzu liquid
chromatographic (Kyoto, Japan) Prominence system,
equipped with a degasser DGU-20A5 Model, SIL-10A
autosampler, two high pressure pumps LC-20AT, a SPD-
M10Avp photodiode array detector (DAD) and a CBM
20A interface. Data collection was performed using LC
Solution software. Analysis was carried out on the analyt-
ical RP-18A SynergiW C18 column (5 μm, 250 × 4.6 mm
i.d., Phenomenex, Torrance, CA, USA) with a RP-18A C18
guard column (4 μm, 4 × 3 mm, Phenomenex, Torrance,
CA, USA) using a gradient elution at 1.0 mL/min with a
mobile phase consisting of water (A) and acetonitrile (B).
Initially, an exploratory gradient from 5 to 100% (B) in
60 min was run as suggested by Snyder et al. (1997) [18].
After optimization, the gradient elution condition used
was: 30-40% (B) in 5 min, 40-68% (B) in 18 min, 68-100%
(B) in 21 min, maintained in 100% (B) for 10 min. The re-
turn to initial chromatographic conditions (100-30% B)
was doing in 10 min, followed by column conditioning for
10 min. The photodiode array detector was set at 205 nm
for acquiring the chromatograms.
Samples of extract and diosgenin were dissolved in
methanol:water (1:1 v/v) and methanol, respectively, at
concentrations of 1.0 mg/mL each, and submitted to fil-
tration through a cellulose membrane (pore diameter of
0.45 μm). Identification was based on co-injection of the
standard compound and comparisons of absorption
spectra.
Animals
Male and female Wistar rats (150-200 g) and male Swiss
mice (24-30 g) were obtained from the Tiradentes Uni-
versity (Sergipe, Brazil). The animals were kept at con-
ventional temperature conditions (20 ± 1°C) and lodged
in polypropylene cages with food and water available ad
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6 pm). Experimental protocols were approved by the
Ethical Committee in Animal Care of the Tiradentes
University (CEPA/UNIT #110310R) and all procedures
were carried out in accordance with Animal Care. The
experiments were performed between 7 am and 5 pm.
Antinociceptive study
Acetic acid-induced writhing
This study was performed according to Broadbear et al.
(1994) [19] with alterations [6,20-22]. Mice (n = 6, per
group) were injected intraperitoneally (i.p.) with 0.85%
acetic acid at a dose of 10 ml/ kg. One hour before the
acetic acid injection, the mice were pretreated orally (per
os or p.o.) with DV (100, 200 and 400 mg/kg, per os or
p.o.), morphine (MOR, 3 mg/kg, i.p.) or vehicle (0.9% sa-
line with two drops of tween 80, the solvent for DV,
Control group). Subsequently, writhing was counted for
15 min after a latency period of 5 min.
Formalin-induced pain
The procedure described by Hunskaar and Hole (1987)
[23] was used with slight modifications [6,20-22]. Noci
ception was induced by injecting 20 μl of 1% formalin in
distilled water in the subplantar region of the right hind
paw. Mice (n = 6 per group) were given DV (100, 200 and
400 mg/kg) and vehicle (saline + two drops of tween 80)
(per os or p.o.) 1,0 h prior to formalin injection. The acetyl-
salicylic acid (ASA, 200 mg/kg) and morphine (MOR,
3 mg/kg) were administered i.p. 0.5 hr before formalin in-
jection. These mice were individually placed in a transpar-
ent acrylic glass cage (25 cm × 15 cm × 15 cm)
observation chamber. The amount of time spent licking
the injected paw was indicative of pain. After injection of
formalin, licking time was recorded from 0-5 min (first
phase) and 15–30 min (second phase), representing neuro-
genic and inflammatory pain responses, respectively.
Anti-inflammatory study
Leukocyte migration to the peritoneal cavity: Leukocyte
migration was induced by injection of carrageenan
(500 μg/cavity, i.p., 500 μL) into the peritoneal cavity of
mice 1 h after the administration of DV (100, 200 and
400 mg/kg, per os or p.o.), vehicle (saline 0.9% with two
drops of tween 80) or dexamethasone (2 mg/kg, s.c.,
n = 6) using a modification of the technique previously
described by Bastos et al. (2007) [24]. Mice were eutha-
nized by cervical dislocation 4 h after carrageenan injec-
tion. Shortly afterward, phosphate buffered saline (PBS)
containing EDTA (1 mM, i.p., 10 mL) was injected. Fluid
was collected immediately using a brief massage and
centrifuged (2000 rpm, 5 min) at room temperature.
The supernatant was removed and 1 mL of PBS was in-
troduced to the precipitate. A 10 μL aliquot from thissuspension was dissolved in 200 μL of Turk’s solution
and the total number of cells was counted in a Neubauer
chamber, under an optical microscope. The results were
expressed as leukocyte number per mL. The percentage
of leukocyte inhibition was calculated as (1 – T/C) ×
100, where T represents the leukocyte count of the
treated group and C represents the leukocyte count of
the control group [25].
Toxicological studies
The following methods were performed according to the
Organization for Economic Cooperation and Develop-
ment test guidelines with slight modifications (OECD).
The number of animals of this study was defined in
compliance with Brazilian regulations for in vivo toxico-
logical assays [26].
Subchronic toxicity study
Toxicological assays were performed with 20 male and
20 female rats distributed into 4 groups of 10 animals
(experimental and control groups of male and female
rats). For the subchronic study, the experimental groups
received daily doses of DV (1 g/kg, per os or p.o.) dis-
persed in water (vehicle) over a period of 30 days. The
product was stirred before being administered. The con-
trol groups received water only.
At the end of the period of administration, the animals
were fasted for 12 h and then anesthetized with Keta-
mine (70 mg/kg) and Xylazine (12 mg/kg). Blood (3-
5 ml) was collected by cardiac puncture. Subsequently,
the animals were euthanized and a detailed study of the
gross and microscopic features of the internal organs
was performed, as well as haematological and biochem-
ical analyses of the blood. The shape, size, texture,
consistency and colour of the internal organs (lungs,
heart, liver, stomach, pancreas, uterus/ovaries, brain and
kidneys) were macroscopically observed for any sign of
gross changes. The organs were then collected, weighed
and preserved in 10% phosphate buffered formalin solu-
tion for subsequent histological procedures [4,22,26].
Acute toxicity study
Toxicological assays were performed with 12 male and
12 female rats, which were distributed into 4 groups of 6
animals (experimental and control groups of male and
female rats). The animals received a maximum dose of
5 g/kg by oral administration (gavage). The experimental
groups received DV (5 g/kg) dispersed in water (vehicle),
whereas the control groups received water only. The
product was stirred before being administered [26].
Specific behaviours (sedation, reduced ambulation,
response to touch, analgesia and defecation) were ob-
served and graded for 1, 2, 3 and 4 h after gavage. Fi-
nally, the animals were monitored daily for 14 days to
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of administration, the animals were fasted for 12 h, and
then anesthetized with Ketamine (70 mg/kg) and Xylazine
(12 mg/kg). Blood was collected by cardiac puncture.
Subsequently, the animals were sacrificed and a detailed
study of the gross and microscopic features of the internal
organs was performed, as well as haematological and
biochemical analyses of the blood. The position, shape,
size, texture, consistency, and colour of the internal or-
gans (lungs, heart, liver, stomach, pancreas, uterus/ovar-
ies, brain and kidneys) were observed macroscopically,
looking for any signs of gross changes. The organs were
then collected, weighed and preserved in 10% phosphate




Blood samples were collected into EDTA tubes. Measure-
ments of erythrocytes, haemoglobin, haematocrit, leuko-
cytes, neutrophils, lymphocytes, eosinophils, monocytes,
basophils, VCM, HCM, CHCM, and platelets were deter-
mined using Sysmex Xs1000i automated equipment -
Japan, according to the method described by Morris and
Davey (1999) [27].
Biochemical parameters
Serum was separated from non-heparinised blood and
assayed for serum urea, creatinine, total protein, globulin,
albumin, aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), total bilirubin (TBil), direct bilirubin
(D.Bil), indirect bilirubin (Bil.IND), alkaline phosphatase
(ALP), sodium (Na+), potassium (K+), cholesterol (CHOL),
triglycerides (TRIG), glucose (GLUC) and uric acid. Bio-
chemical parameters were determined by ARCHITECT
C8000 automated equipment (Abbott, USA).
Tissue analysis
Formalin-fixed samples of the internal organs were dehy-
drated, diaphonized and embedded in paraffin according
to protocols for routine histological procedures. Five
micrometre thick sections of the paraffin-embedded
tissues were obtained and stained with haematoxylin-
eosin. Morphological analysis of the histological sections
was performed by light microscopy following a closed
numerical protocol so that the pathologist was not aware
of what group was being evaluated until the end of the
experiment.
Statistical analysis
Student’s t-test (GraphPad Prism 5.01 computer program)
was employed for statistical analysis of the results. The
data obtained from the antinociceptive study were evalu-
ated by one-way analysis of variance ANOVA followed byTukey’s tests. The percentage inhibition by antinociceptive
agent was determined using the following equation:
(Eq. 1) % Inhibition = 100 × (control-experiment)/control.
Statistical evaluation of the consumption of food and
water was carried out using the differentiation factor (f1)
and similarity factor (f2) methods [28]. All values were ex-
pressed as the back transformed mean ± S.D. or SEM.




Qualitative analysis of the extract from DV was performed
by HPLC. Figure 1 shows the chromatographic profile of
this extract presenting good separation and resolution of
peaks. The diosgenin was characterized by retention time
relative to external standard. HPLC-DAD analysis of the




The acetic acid-induced writhing is a standard, simple
and sensitive test for measuring analgesia induced by
both opioids and peripherally acting analgesics [22,29].
According to Duarte et al. (1988) [30], the nociceptive
mechanism involves the processing or release of arachi-
donic acid metabolites via cyclooxygenase (COX) and
prostaglandin biosynthesis during abdominal writhing
induced by acetic acid. In this study DV, in higher doses,
significantly reduced writhing and stretching induced by
i.p. administration of acetic acid solution (0.85% acetic
acid). Significant protective effects were observed in
Figure 2, through the inhibition (%) of nociceptive be-
haviour by 200 mg/kg (46.52%) and 400 mg/kg (38.46%)
(p < 0.0001) doses of DV. MOR (3 mg/kg) had 98.17%
(p < 0.0001) inhibition. These effects are probably related
to the inhibition of PGE2 and PGF2α levels in the peri-
toneal fluid [31] and with the inhibited release of sub-
stance P and other inflammatory molecules such as
serotonin, histamine, bradykinin, and prostaglandins
[22,32].
Formalin-induced pain
As shown by Tjølsen et al. (1992) [32], the formalin test
involves continuous pain generated by injured tissue, and
is a very useful method, not only for assessing antinoci
ceptive drugs, but also to help elucidate the mechanism
of action. The neurogenic phase is probably a direct
result of C-fibre activation due to the peripheral stimulus
in the paw and reflects centrally mediated pain with the
release of substance P. The late phase appears to be
dependent on the combination of inflammation in the
peripheral tissue with the release of histamine, serotonin,
Figure 2 Effects of Dioscorea villosa (DV) on the acetic
acid-induced writhing test in mice. Vehicle (control, per os or p.o.),
morphine (MOR 3 mg/Kg, i.p) and DV (100, 200 and 400 mg⁄kg, per
os or p.o.) were administered 1,0 hr before acetic acid injection. Each
column represents mean ± S.E.M. (n = 6). ***p < 0.0001 versus control
(ANOVA followed by Tukey’s test).
Figure 1 HPLC-DAD chromatogram at 205 nm of the extract from Dioscorea villosa.
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had analgesic effects in both the first and second phase
of formalin-induced pain (p < 0.0001). In the first phase
(Figure 3a) neurogenic-induced pain not was blocked
at 100 (27.29% inhibition) or 200 mg/kg (p > 0.05)
(30.06% inhibition), only the 400 mg/kg (46.06% inhi-
bition) dose significantly blocked neurogenic pain.
ASA (200 mg/kg; 52.2% inhibition) and MOR (98.76%
inhibition) were significantly active in first phase (p <
0.05). This result shows the dose of 400 mg/kg is anal-
gesic. In the second phase, representing inflammatory
pain, DV significantly reduced licking time compared
to the control group at 200 (51.36% inhibition) and
400 mg/kg (66.7% inhibition) (Figure 3b). Thus, higher
doses of the extract were able to block both phases of
the formalin response, but the effect was more promin-
ent in the second phase.
Together these results support the hypothesis that DV
participates in the inhibition of prostaglandin synthesis
or the inhibition of proinflammatory cytokines (such as
Figure 4 Effect of Dioscorea villosa (DV) on leukocyte migration
into the peritoneal cavity induced by carrageenan in mice.
Groups of rats were pre-treated with vehicle (control group, 10 mL/Kg,
per os or p.o.), dexamethasone (Dexa, 2 mg/kg, s.c.), or DV in
concentrations of 100, 200 and 400 mg/kg (per os or p.o.) 60 min
before carrageenan (500 μg/cavity, 500 μL, i.p.)-induced peritonitis.
Cell counts were performed at the time 4 h after the injection of
carrageenan. Value represents the mean ± S.E.M. *p < 0.05 and **
P < 0.001 when compared to control group. ANOVA followed by Tukey
test (n = 6, per group).
Figure 3 Effects of Dioscorea villosa (DV) on the formalin-induced nociception in mice (first phase – Figure 2a and second phase Figure
2b). Vehicle (control) and DV (100, 200 and 400 mg⁄kg) were administered per os or p.o. 1,0 hr before formalin injection. The acetylsali-cylic acid
(ASA) or morphine (MOR) were administered i.p. 0.5 hr before formalin injection. Each column represents mean ± S.E.M. (n = 6). **p < 0.001
or ***p < 0.0001 versus control (ANOVA followed by Tukey’s test).
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central pathways.
Anti-inflammatory studies
The mechanism involved in the genesis of the carra
geenan-induced oedema can cause the release of
prostaglandins and kinins, as well as other substances
such as prostaglandins, histamine, serotonin and
leukotrienes. This type of oedema is dependent on
the mobilisation of neutrophils [36-40]. The anti-
inflammatory effect of DV can be observed from its
inhibitory action on carrageenan-induced leukocyte
migration to the peritoneal cavity 4 h after stimulus
with all doses (p = 0.0027) compared to the control
group, as shown in Figure 4. Significant inhibition ef-
fects of 40.41, 32.96 and 31.66% were observed for
the 100, 200 and 400 mg/kg doses of DV, respect-
ively. These results confirm the therapeutic activity of
the plant when compared with vehicle, which did not
exhibit activity. An effect of the drug dexamethasone
(2 mg/kg, s.c.) on inhibited leukocyte migration was
observed (31.75%), compared with the control group.
As described by Loram et al., (2007) [41], inflamma-
tion induced by carrageenan involves cell migration,
plasma exudation and production of mediators, such
as interleukin (IL)-1β, IL-6 and tumour necrosis
factor-alpha (TNF-α), a cytokine-induced neutrophil.
These mediators are able to recruit leukocytes in
several experimental models [25]. The decreased
leukocyte migration in the carrageenan test suggests
that DV activity may inhibit the synthesis of many in-
flammatory mediators whose involvement in cell mi-
gration is well established. These results may be
related to the presence of diosgenin, a steroidal
saponin found in several plants including species of
Solanum and Dioscorea [42]. Previous investigationshave shown that diosgenin plays an important
pharmacological role as an anti-inflammatory agent




In the acute toxicity test, a 5 g/kg dose of DV did not
cause the death of any rats during a 14-day observation
period. In addition, no change in body weight was ob-
served in the experimental groups (Table 1). Because re-
duction in body weight gain and internal organ weights
Table 2 Body weight of Wistar rats obtained after 30
consecutive days of treatment with Dioscorea villosa dry
extract (DV) 1000 mg/kg given by oral route
Control DV 1000 mg/kg








Male 0 352.6 ± 4.5 0.00 278.8 ± 5.1 0.00
10 350.3 ± 4.4 −0.65 293.13 ± 4.9*** 5.14
20 362.2 ± 4.5 2.72 305.00 ± 3.9*** 9.40
30 364.0 ± 4.0 3.23 310.15 ± 4.2*** 11.24
Female 0 195.1 ± 2.6 0.00 159.0 ± 3.5 0.00
10 200.4 ± 3.5 2.72 176.0 ± 3.1* 10.69
20 204.9 ± 3.1 5.02 189.7 ± 2.5*** 19.30
30 214.9 ± 4.2 10.15 196.4 ± 3.1*** 23.50
Values are expressed as mean ± S.E.M. (n = 10 animals/group). * Significant
difference from control group (*p < 0.05; **p < 0.01; ***p < 0.001 by ANOVA,
followed by Tukey test).
Table 1 Body weight of Wistar rats obtained after acute
oral treatment with Dioscorea villosa dry extract at a
daily dose of 5 g/Kg (single dose) given by oral route
Control DV 5000 mg/kg








Male 0 332.14 ± 4.0 0.00 282.00 ± 5.2 0.00
7 338.00 ± 5.5 1.76 284.00 ± 5.0 0.71
14 345.43 ± 4.9 4.00 291.10 ± 5.6 3.24
Female 0 212.90 ± 4.6 0.00 195.50 ± 5.8 0.00
07 214.00 ± 5.2 0.54 198.90 ± 5.3 1.73
14 218.00 ± 5.2 2.42 203.10 ± 6.4 3.92
Values are expressed as mean ± S.E.M. (n = 07 animals/group).
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[44-46], our data suggest that oral administration of
DV is not toxic. Surprisingly, one treated female
(from day 5 to day 11) and two control (day 11), as
well as one treated male (days 12 and 13) and two
control (from day 12 to day 15) showed soft faeces in
experimental day. Although it has been previously
demonstrated that the ingestion of large amounts of
the tubers can cause diarrhea [47], the fact that ani-
mals of both control and treated groups exhibited
such alterations suggests that these data are unlikely
to be side effects associated with administration of
the dry extract. We also verified that the water con-
sumption was decreased in treated male rats, but not
in females, in relation to the control groups. Because
no other behavioural changes were noticed in this
study, it is possible to assert that the increased water
consumption was unlikely to be related to any toxic
effect of the acute experimental treatment.
On the other hand, in the subchronic assay (Table 2),
animals of both genders treated with DV exhibited
weight gain at rates significantly higher than control
animals (p < 0.0001). These results might be related to
the fact that diosgenin, one of the major chemical compo-
nents of DV extract [9], is hypothesised to work as a bio-
chemical precursor of progesterone and other corticoids
[14]. Thus, the gain in body weight could be attributed to
corticoid-associated fluid retention in response to the con-
tinuous exposure to the dry extract. This theory is sup-
ported by the absence of significant differences in food
and water intake between treated and control groups.
As shown in Tables 3 and 4, there were distinct pat-
terns of weight gain in some internal organs in male and
female rats treated with DV in both acute and sub-
chronic assays. We hypothesised that changes in the
weight of these organs might be a result of specific
activity of the chemical components of the extract in
parenchymal cells, leading to mild hypertrophic or
hyperplasic effects that are undetectable by gross or light
microscopic examinations. In addition, because DV has
been regarded as a phytohormone [8], differences in the
number and distribution of hormone receptors in differ-
ent genders might explain the fact that distinct organs
were affected in male and female rats. However, further
investigations are required in order to confirm this
theory.
Haematological analysis
Despite significant differences in some haematological
parameters were verified in control and treated groups
of both genders (Table 5 and 6), the data obtained in the
acute and subchronic assays were within reference value
ranges described in previous studies [21], suggesting that
such alterations hold no clinical relevance [48]. Therefore,the slight alterations observed in this study concerning
those parameters, particularly those in the control groups,
might be associated to biological variation related to the
nature and management of the animals in the different re-
search vivaria.Biochemical parameters
In the subchronic assay (Table 7), the increased bio-
chemical level of ALP and D.BIL in treated rats (male
and female) might be suggestive of cholestatic alterations
secondary to changes in biliary flow [49]. In addition, in-
creased levels of AST and ALT suggesting possible dam-
age to the hepatocytes [49] were only observed in the
treated females. However, the treated rats (both males
and female) appeared to sustain the normal liver func-
tion, as there was no reduction in the production of pro-
tein or albumin when compared to the treated group.
Table 3 Changes in the organ weight of rats Wistar after acute oral treatment with Dioscorea villosa at a daily dose of
5 g/Kg (single dose)
Groups
Organs FC FT MC MT
Heart 0.4729 ± 0.015 0.4543 ± 0.011 0.4114 ± 0.010 0.3929 ± 0.015
Lungs 0.7343 ± 0.024 0.6700 ± 0.027 0.5529 ± 0.023 0.4786 ± 0.025
Liver 3.309 ± 0.1047 3.506 ± 0.1595 2.947 ± 0.080 2.960 ± 0.1238
Brain 0.7671 ± 0.022 0.8757 ± 0.022** 0.4914 ± 0.027 0.5414 ± 0.031
Kidneys 0.8071 ± 0.021 0.8271 ± 0.030 0.8329 ± 0.043 0.7671 ± 0.030
Stomach 0.8671 ± 0.032 0.7771 ± 0.015* 0.6571 ± 0.024 0.5686 ± 0.030*
Uterus/ovaries 0.4629 ± 0.089 0.7486 ± 0.097 - -
Pancreas 0.4843 ± 0.092 0.5614 ± 0.060 0.3371 ± 0.097 0.3786 ± 0.043
FC control female, FT treated female, MC control male, MT treated male. Data are expressed as mean ± S.D., n = 6; * Significant difference from control group ( *p
< 0.05, **p < 0.01 and ***p < 0.001) (test t).
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http://www.biomedcentral.com/1472-6882/13/195The values of urea and creatinine were not increased in
the blood, indicating that renal function was not
affected. The treated rats (male and female) showed
hypernatraemia and hyperglycaemia compared with the
control group (p < 0.05). Because DV has been reported as
a corticoid precursor, these data are likely related to renal
sodium retention and increased glycogenesis [50] pro-
moted by saponins derived from the herbal dry extract.
As shown in Table 8, the biochemical results of the
acute assay denoted isolated elevation of ALT in fe-
males and ALP in both sexes, which may be indica-
tive of superficial injury of the hepatocyte [51]. The
treated males presented a decrease in the production
of total protein and albumin, suggesting impairment
of liver function [52]. As in the subchronic test, only
the females showed hyperglycaemia. On the other
hand, both males and females treated rats had
hypocholesterolaemia when compared to the control
group. Because the treatment of menopause with
synthetic hormones might lead to increases inTable 4 Changes in the organ weight (g/%) of rats after subc
dose of 1000 mg/kg for 30 days
Grou
Organs FC FT
Heart 0.426 ± 0.055 0.447 ± 0
Lungs 0.631 ± 0.097 0.677 ± 0
Liver 3.084 ± 0.279 3.620 ± 0
Brain 0.783 ± 0.055 0.892 ± 0.
Kidneys 0.704 ± 0.040 0.843 ± 0.0
Stomach 0.671 ± 0.065 0.760 ± 0
Uterus/ovaries 0.363 ± 0.052 0.409 ± 0
Pancreas 0.528 ± 0.195 0.526 ± 0
FC control female, FT treated female, MC control male, MT treated male. Data are ex
control and Dioscorea villosa group *p < 0.05, **p < 0.01 and ***p < 0.001 (test t).cholesterol [53], our findings suggest that DV dry ex-
tract could be regarded as a safer phytomedicine to
control climacteric symptoms without causing side
effects on serum fat levels. Despite some significant
differences in other biochemical parameters observed
in this assay, they were within the reference values
for the species studied. None of these significant dif-
ferences were considered to be toxicologically rele-
vant due to a lack of dose-response relationship,
relatively low magnitude of change, absence of occur-
rence in both sexes, and/or the lack of important
changes in related clinical parameters. Also, no ab-
normalities or further evidence of histopathological
changes were seen in any of the control or treated
rats of both sexes.
Tissue analysis
Pathological examination of tissues indicated no detect-
able abnormality, either in weight or in appearance, be-
tween control and test groups. Moreover, the organs ofhronic oral treatment with Dioscorea villosa at a daily
ps
MC MT
.049 0.372 ± 0.021 0.414 ± 0.039
.067 0.523 ± 0.065 0.498 ± 0.093
.518* 2.678 ± 0.083 2.993 ± 0.497
071** 0.511 ± 0.035 0.594 ± 0.059**
56*** 0.756 ± 0.032 0.794 ± 0.041
.136 0.572 ± 0.059 0.507 ± 0.063*
.068 - -
.057 0.553 ± 0.165 0.397 ± 0.090*
pressed as mean ± S.D., n = 10; * Indicate statistical difference between the
Table 5 Effect of Dioscorea villosa after oral administration (single dose-5 g/Kg) on hematologic parameters
considering sex interaction in Wistar rats (n = 6)
Groups
Parameters FC FT R1 MC MT R2
Leukocyte (×103/mm3) 5.17 ± 0.853 7.18 ± 0.385 4.7 – 12.98 a 7.03 ± 0.677 7.70 ± 1.220 5.7 – 13.9 a
Erythrocytes (×106/mm3) 7.89 ± 0.395 8.60 ± 0.135 7.3 – 8.64 a 9.56 ± 0.249 9.66 ± 0.230 6.7 – 8.6a
Hemoglobin (g/dl) 13.43 ± 0.685 14.87 ± 0.225 13.2 – 15.1 a 15.59 ± 0.417 15.91 ± 0.309 12.8 – 15.9 a
Hematocrit (%) 42.93 ± 2.166 43.37 ± 0.569 39.1 – 48.5 a 48.43 ± 1.206 45.60 ± 0.649 39.1 – 48.7 a
VCM (fl) 54.40 ± 0.727 49.87 ± 0.201*** 49.1 – 62.5 a 50.70 ± 0.439 47.21 ± 0.472*** 50 – 59 a
HCM (pg) 17.00 ± 0.089 17.08 ± 0.065 16.6 – 18.9 a 16.31 ± 0.112 16.5 ± 0.104 17.0 – 19.5 a
CHCM (g/dl) 31.28 ± 0.433 34.27 ± 0.071*** 29.9 – 34.9 a 32.17 ± 0.191 34.91 ± 0.265*** 30.5 – 35.3 a
Platelets (×106/mm3) 1070 ± 74.760 1246 ± 59.830 757 – 1476 a 1198 ± 41.10 1141 ± 73.77 837 – 1455 a
Neutrophil (%) 48.40 ± 7.259 36.97 ± 2.070 5.4 – 37.5 a 45.84 ± 1.335 48.80 ± 3.384 17.1 – 47.9 a
Lymphocyte (%) 47.46 ± 5.432 57.73 ± 2.464 57.9 – 90.0 a 48.26 ± 1.716 46.09 ± 2.773 48.7 – 78.1 a
Monocyte (%) 2.857 ± 0.739 3.43 ± 0.814 0.6 – 7.9 a 3.47 ± 0.201 3.63 ± 0.432 1.0 – 6.5 a
Eosinophil (%) 1.60 ± 0.323 1.30 ± 0.206 0.2 – 4.5 a 0.16 ± 0.031 0.08 ± 0.016 0.3 – 4.0 a
FC (control female), FT (treated female), MC (control male), MT (treated male). N = 06. Data are expressed as mean ± S.D. * Indicate statistical difference between
the control and treated group *p < 0.05, **p < 0.01 and ***p < 0.001 (test t). R1 (reference female); R2 (reference male); a Melo (2012).
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http://www.biomedcentral.com/1472-6882/13/195both groups were unremarkable and comparable within
each sex. The tissue analysed did not exhibit histological
changes, except for the liver, which presented foci of
intracellular accumulation of fatty droplets, consistent
with microvesicular steatosis, in the acute and subchronic
assays in both genders.
While microvesicular steatosis has usually been
described in association with severe clinical cases of
hepatic damages, previous finding suggest that it can be
present without liver dysfunction or hepatotoxicity [54].
Therefore, it seems that further investigations are still
required to clarify the mechanisms underlying theTable 6 Effect of Dioscorea villosa after oral administration (3
rats (n = 10)
Parameters FC FT
Leukocyte (×103/mm3) 5.28 ± 0.896 7.16 ± 1.604
Erythrocytes (×106/mm3) 8.15 ± 0.262 8.76 ± 0.421
Hemoglobin (g/dl) 14.38 ± 0.473 15.17 ± 0.566 1
Hematocrit (%) 40.34 ± 1.571 42.11 ± 1.515 3
VCM (fl) 49.49 ± 0.737 48.27 ± 1.250 4
HCM (pg) 17.63 ± 0.149 17.28 ± 0.405 1
CHCM (g/dl) 35.65 ± 0.299 35.82 ± 0.323 2
Platelets (×106/mm3) 1115.30 ± 115.039 1356.30 ± 90.371*** 7
Neutrophil (%) 36.64 ± 2.587 24.35 ± 4.461***
Lymphocyte (%) 58.49 ± 3.222 71.59 ± 4.228*** 5
Monocyte (%) 4.42 ± 0.947 3.90 ± 0.587
Eosinophil (%) 0.45 ± 0.534 0.16 ± 0.101
FC (control female), FT (treated female), MC (control male), MT (treated male). N = 1
the control and treated group *p < 0.05, **p < 0.01 and ***p < 0.001 (test t). R1 (refepathogenesis of microvesicular steatosis, particularly in
order to better establish the clinical implications of this
morphological hepatic change. In addition, alterations
in biochemical measurements, indicative of cholestasis
(subchronic test) and represented histologically as accu-
mulation of bilirubin in the sinusoidal spaces, hepato-
cyte injury, and inflammation (accumulation of immune
cells) were not confirmed by the histological analysis,
suggesting that these supposed disturbances were not
expressive enough to promote morphological changes
in the hepatic tissue. These findings indicate that oral
DV promotes no morphological changes in the vital0 days) on hematologic parameters interaction in Wistar
R1 Female MC MT R1 Male
4.7 – 12.98a 8.20 ± 1.959 8.37 ± 1.376 5.7 – 13.9 a
7.3 – 8.64 a 9.40 ± 0.339 9.62 ± 0.303 6.7 – 8.6 a
3.2 – 15.1 a 15.65 ± 0.602 16.33 ± 0.409* 12.8 – 15.9 a
9.1 – 48.5 a 42.53 ± 1.497 44.50 ± 0.818** 39.1 – 48.7 a
9.1 – 62.5 a 45.24 ± 0.964 46.33 ± 1.029* 50.0 – 59.0 a
6.6 – 18.9 a 16.64 ± 0.236 17.0 ± 0.252** 17.0 – 19.5a
9.9 – 34.9 a 36.80 ± 0.573 36.70 ± 0.472 30.5 – 35.3 a
57 – 1476 a 1111.20 ± 135.711 1183.89 ± 66.196 837 – 1455 a
5.4 – 37.5 a 41.80 ± 4.007 30.32 ± 5.052*** 17.1 – 47.9 a
7.9 – 90.0 a 51.43 ± 3.969 64.18 ± 5.332*** 48.7 – 78.1 a
0.6 – 7.9 a 6.12 ± 1.353 4.70 ± 1.983 1.0 – 6.5 a
0.2 – 4.5 a 0.65 ± 0.701 0.23 ± 0.150 0.3 – 4.0 a
0. Data are expressed as mean ± S.D. * Indicate statistical difference between
rence female); R2 (reference male); a Melo (2012).
Table 7 Serum biochemical findings in rats treated with Dioscorea villosa at a daily dose of 1000 mg/kg for 30 days
Parameters FC FT R1 Female MC MT R1 Male
Albumin (g/dL) 3.05 ± 0.284 3.33 ± 0.050** 2.6 – 3.4 a 2.75 ± 0.085 3.10 ± 0.122*** 2.7 – 3.2 a
ALP (U/L) 35.90 ± 7.325 86.55 ± 15.428*** 63 – 138 a 48.20 ± 9.175 92.00 ± 17.356*** 79 – 196 a
TGP or ALT (U/L) 36.80 ± 3.765 46.11 ± 5.710*** 26 – 60 a 51.10 ± 3.814 53.55 ± 4.825 36 – 58 a
TGO or AST (U/L) 68.90 ± 13.211 84.66 ± 15.851* 83 – 184 a 99.30 ± 24.097 87.78 ± 18.633 81 – 180 a
Creatinine (mg/dL) 0.53 ± 0.022 0.49 ± 0.022** 0.4 – 0.7 a 0.45 ± 0.032 0.49 ± 0.027* 0.44 – 0.64 a
GLUC (mg/dL) 128.70 ± 17.827 150.55 ± 9.302** 61 – 147 a 139.70 ± 18.607 146.22 ± 12.163 79 – 144.0 a
K+ (mmol/L) 4.07 ± 0.200 4.755 ± 0.557** 3.7 – 5.7 a 4.86 ± 0.529 5.49 ± 1.128 4.2 – 6.4 a
Na+ (mmol/L) 132.60 ± 0.699 138.55 ± 2.651*** 132 - 146 a 132.90 ± 1.197 140.66 ± 2.061*** 135 - 144 a
Total Protein (g/dL) 3.50 ± 0.271 6.16 ± 0.212*** 6.1 – 7.4 a 3.33 ± 0.125 5.99 ± 0.271 5.4 – 6.6 a
TRIG (mg/dL) 29.20 ± 4.315 31.33 ± 6.633 39 – 130 a 34.70 ± 3.683 30.00 ± 6.422 42 – 160 a
Urea (mg/dL) 41.50 ± 4.972 40.00 ± 4.528 30 – 57 a 36.80 ± 3.293 37.78 ± 2.438 30 – 42 a
Uric acid (mg/dL) 1.83 ± 0.374 1.97 ± 0.630 1.2 – 2.5 a 1.53 ± 0.327 1.60 ± 0.367 0.9 – 2.0 a
Bil.IND (mg/dL) 0.15 ± 0.227 0.06 ± 0.055 0.01 – 0.01 a 0.07 ± 0.005 0.07 ± 0.050 0.01 – 0.01 a
D.Bil (mg/dL) 0.02 ± 0.006 0.10 ± 0.000*** 0.01 – 0.03 a 0.02 ± 0.005 0.10 ± 0.000 0.01 – 0.03 a
TBil (mg/dL) 0.10 ± 0.000 0.15 ± 0.055* 0.07 – 0.09 a 0.10 ± 0.000 0.16 ± 0.055 0.07 – 0.09 a
FC (control female), FT (treated female), MC (control male), MT (treated male), N = 10. Data are expressed as mean ± S.D. * Indicate statistical difference between
the control and treated group *p < 0.05, **p < 0.01 and ***p < 0.001 (test t). R1 (reference female); R2 (reference male) a Melo (2012).
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duces no toxicological effects.
Conclusion
It can be concluded that DV is effective as an analgesic
in two pain models, and provides expressive anti-inflam
matory effect. The extract presented no acute andTable 8 Serum biochemical findings in rats Wistar treated wit
Parameters FC FT R1
Albumin (g/dL) 3.06 ± 0.097 3.06 ± 0.030 2.6
ALP (U/L) 48.00 ± 4.669 73.43 ± 5.622** 63
TGP or ALT (U/L) 40.60 ± 3.614 51.57 ± 2.999* 26
TGO or AST (U/L) 106.80 ± 8.509 86.00 ± 5.499 83
Creatinine (mg/dL) 0.49 ± 0.007 0.5329 ± 0.015 0.4
GLUC (mg/dL) 131.40 ± 7.593 161.7 ± 5.222** 61
K+ (mmol/L) 4.05 ± 0.193 4.06 ± 0.146 3.7
Na+ (mmol/L) 133.40 ± 0.812 134.10 ± 0.459 132
Total Protein (g/dL) 4.17 ± 0.063 4.27 ± 0.052 6.1
TRIG (mg/dL) 32.75 ± 2.136 42.57 ± 3.683 39
Urea (mg/dL) 33.60 ± 1.503 37.14 ± 1.668 30
Uric acid (mg/dL) 1.65 ± 0.132 2.04 ± 0.169 1.2
Bil.IND (mg/dL) 0.08 ± 0.004 0.08 ± 0.003 0.01
D.Bil (mg/dL) 0.02 ± 0.004 0.02 ± 0.003 0.01
TBil (mg/dL) 0.10 ± 0.004 0.10 ± 0.003 0.07
CHOL (mg/dL) 60.60 ± 2.315 56.57 ± 2.599 55
FC (control female), FT (treated female), MC (control male), MT (treated male). N = 1
the control and treated group *p < 0.05, **p < 0.01 and ***p < 0.001 (test t). R1 (refesubchronic toxicity when administered by oral route.
Further studies are currently in progress to clarify the
precise mechanisms of action of DV on nociception and
inflammation. However, the antinociceptive and anti-
inflammatory actions demonstrated in Dioscorea villosa
in this study support at least in part, the ethnomedicinal
use of this plant.h Dioscorea villosa at a single dose (5 g/kg)
Female MC MT R1 Male
– 3.4 a 3.03 ± 0.112 2.73 ± 0.042* 2.7 – 3.2 a
– 138 a 80.00 ± 4.889 109.4 ± 6.575** 79 – 196 a
– 60 a 68.43 ± 7.234 62.43 ± 2.653 36 – 58 a
– 184 a 160.9 ± 15.33 121.1 ± 14.12 81 – 180 a
– 0.7 a 0.59 ± 0.019 0.51 ± 0.007** 0.44 – 0.64 a
- 147 a 157.6 ± 7.030 172.7 ± 7.819 79 – 144 a
– 5.7 a 5.814 ± 0.370 5.07 ± 0.185 4.2 – 6.4 a
– 146 a 135.6 ± 1.478 135.3 ± 0.356 135 – 144 a
– 7.4 a 4.614 ± 0.230 3.81 ± 0.103** 5.4 – 6.6 a
– 130 a 46.57 ± 3.077 54.57 ± 6.294 42 – 160 a
– 57 a 47.43 ± 1.251 37.57 ± 1.232 30 – 42 a
– 2.5 a 3.37 ± 0.377 2.41 ± 0.298 0.9 – 2.0 a
– 0.01 a 0.07 ± 0.011 0.08 ± 0.003 0.01 – 0.01 a
– 0.03 a 0.03 ± 0.011 0.02 ± 0.003 0.01 – 0.03 a
– 0.09 a 0.10 ± 0.010 0.10 ± 0.003 0.07 – 0.09 a
– 79 a 59.57 ± 3.191 50.14 ± 2.405 46 – 101 a
0. Data are expressed as mean ± S.D. * Indicate statistical difference between
rence female); R2 (reference male); a Melo (2012).
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